• S. K. REEHANA Department of Pharmaceutical Analysis, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur 522510, Andhra Pradesh, India
  • K. SUJANA Department of Pharmaceutical Analysis, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur 522510, Andhra Pradesh, India



LC-MS/MS, Tucatinib, Method development, Validation, Degradation pathways


Objective: The current study focused on the development, validation, and characterization of forced degradation products using LC-MS/MS.

Methods: A simple, selective, validated and well-defined isocratic HPLC methodology for the quantitative determination of Tucatinib at a wavelength of 239 nm. An isocratic elution of samples was performed on an Inertsil ODS (250x4.6 mm, 5m) column with a mobile phase of 70:30v/v Acetonitrile and formic acid (0.1%) delivered at a flow rate of 1.0 ml/min. MS/MS was used to characterize degradation products formed in the forced degradation study. The validation and characterization of forced degradation products were performed in accordance with ICH guidelines.

Results: Over the concentration range of 5-100μg/ml, a good linear response was obtained. Tucatinib's LOD and LOQ were determined to be 0.05 and 0.5, respectively. According to standard guidelines, the method was quantitatively evaluated in terms of system suitability, linearity, precision, accuracy, and robustness, and the results were found to be within acceptable limits. The drug was degraded under acidic, alkaline, and reduction conditions in forced degradation studies.

Conclusion: The method was found to be applicable for routine tucatinib analysis. Because no LC-MS/MS method for estimating tucatinib and its degradation products has been reported in the literature. There is a need to develop a method for studying the entire tucatinib degradation pathway.


Download data is not yet available.


Gross Stefan, Rahal Rami, Stransky Nicolas, Lengauer Christoph, Hoeflich Klaus P. Targeting cancer with kinase inhibitors. J Clin Invest. 2015;125(5):1780-9. doi: 10.1172/JCI76094, PMID 25932675.

Jänne Pasi A, Gray Nathanael, Settleman Jeff. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov. 2009;8(9):709-23. doi: 10.1038/nrd2871, PMID 19629074.

Mitri Zahi, Constantine Tina, O’Regan Ruth. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193. doi: 10.1155/2012/743193.

Roy Vivek, Perez Edith A. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist. 2009;14(11):1061-9. doi: 10.1634/ theoncologist.2009-0142, PMID 19887469.

Seguin Laetitia, Kato Shumei, Franovic Aleksandra, Camargo M Fernanda, Lesperance Jacqueline, Elliott Kathryn C, Yebra Mayra, Mielgo Ainhoa, Lowy Andrew M, Husain Hatim, Cascone Tina, Diao Lixia, Wang Jing, Wistuba Ignacio I, Heymach John V, Lippman Scott M, Desgrosellier Jay S, Anand Sudarshan, Weis Sara M, Cheresh David A. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014;16(5):457-68. doi: 10.1038/ncb2953, PMID 24747441.

Zink Daniele, Fischer Andrew H, Nickerson Jeffrey A. Nuclear structure in cancer cells. Nat Rev Cancer. 2004;4(9):677-87. doi: 10.1038/nrc1430, PMID 15343274.

Vlastaridis Panayotis, Papakyriakou Athanasios, Chaliotis Anargyros, Stratikos Efstratios, Oliver Stephen G, Amoutzias Grigorios D. The pivotal role of protein phosphorylation in the control of central yeast metabolism. G3 (Bethesda). 2017;7(4):1239-49. doi: 10.1534/g3.116.037218, PMID 28250014.

Sharma Saumya, Guthrie Patrick H, Chan Suzanne S, Haq Syed, Taegtmeyer Heinrich. Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc Res. 2007;76(1):71-80. doi: 10.1016/j.cardiores.2007.05.004, PMID 17553476.

Yu Jiabo, Sun Xiang, Goie Jian Yi Gerald, Zhang Yongliang. Regulation of host immune responses against influenza virus infection by mitogen-activated protein kinases (MAPKs). Microorganisms. 2020;8(7):1067. doi: 10.3390/microorganisms8071067, PMID 32709018.

Cargnello Marie, Roux Philippe P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50-83. doi: 10.1128/MMBR.00031-10, PMID 21372320.

Hill Michelle M, Hemmings Brian A. Inhibition of protein kinase B/Akt. Implications for cancer therapy. Pharmacol Ther. 2002;93(2-3):243-51. doi: 10.1016/s0163-7258(02)00193-6, PMID 12191616.

Xie Jiuyong, Weiskirchen Ralf. What Does the “AKT” stand for in the name “AKT Kinase”? some historical comments. Front Oncol. 2020;10:1329. doi: 10.3389/fonc.2020.01329, PMID 32850422.

Lademann Juergen, Martschick Anja, Kluschke Franziska, Richter Heike, Fluhr Joachim W, Patzelt Alexa, Jung Sora, Chekerov Radoslav, Darvin Maxim E, Haas Norbert, Sterry Wolfram, Zastrow Leonhard, Sehouli Jalid. Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy. Skin Pharmacol Physiol. 2014;27(2):66-70. doi: 10.1159/000351801, PMID 23969763.

Rosenbeck Lindsay, Kiel Patrick J. Images in clinical medicine. Palmar-plantar rash with cytarabine therapy. N Engl J Med. 2011;364(3):e5. doi: 10.1056/NEJMicm1006530, PMID 21247311.

Manov Irena, Motanis Helen, Frumin Idan, Iancu Theodore C. Hepatotoxicity of anti-inflammatory and analgesic drugs: ultrastructural aspects. Acta Pharmacol Sin. 2006;27(3):259-72. doi: 10.1111/j.1745-7254.2006.00278.x, PMID 16490160.

Brocklehurst Paul, Tickle Martin, Glenny Anne Marie, Lewis Michael A, Pemberton Michael N, Taylor Jennifer, Walsh Tanya, Riley Philip, Yates Julian M. Systemic interventions for recurrent aphthous stomatitis (mouth ulcers). Cochrane Database Syst Rev. 2012;9(9):CD005411. doi: 10.1002/14651858.CD005411.pub2, PMID 22972085.

Lawton CL. Obesity: a disorder of appetite. Pract Diab Int. 1993;10(1):10-2. http://doi:10.1002/pdi.1960100105, doi: 10.1002/pdi.1960100105.

Viniol Annika, Keunecke Christian, Biroga Tobias, Stadje Rebekka, Dornieden Katharina, Bösner Stefan, Donner Banzhoff Norbert, Haasenritter Jorg, Becker Annette. Studies of the symptom abdominal pain- a systematic review and meta-analysis. Fam Pract. 2014;31(5):517-29. doi: 10.1093/fampra/cmu036, PMID 24987023.

Potturi Ramadevi, Kantipudi Rambabu. Bio analytical method development and validation for Ezetimibe and Pitavastain and its applications to pharmacokinetic studies in Rabbit plasma by using LCMS/MS. IJRPS 2020;11(4):7854-62. doi: 10.26452/ijrps.v11i4.4670.

Eluru Asha. Surendra Babu K. Bio analytical method development and validation for Aplidine in rat plasma and their pharmacokinetic studies by LCMS. World J Pharm Pharm Sci. 2019;8:1201-9.

Ramchandran D, Kethipalli Anita, Krishnamurthy Mannam. Bioanalytical method development and validation of daunorubicin and cytrarabine in rat plasma by LC-MS/MS and its application in pharmacokinetic studies. J Pharm Sci Res. 2020;12:381-6.

Shalini K, Ilango K. Development, evaluation and RP-HPLC method for simultaneous estimation of quercetin, ellagic acid and kaempferol in a polyherbal formulation. Int J Appl Pharm. 2021;13:183-92.

Malak Y, Al-Bathish AA, gazy MK, El-Jamal. Rp-hplc and chemometric methods for the determination of two anti-diabetic mixtures; metformin hydrochloride-canagliflozin and metformin hydrochloride-gliclazide in their pharmaceutical formulation. Int J Pharm Pharm Sci. 2020;12:83-94.

Girija KS, Kasimala BB, Anna VR. A new high-performance liquid chromatography method for the separation and simultaneous quantification of eptifibatide and its impurities in pharmaceutical injection formulation. Int J Appl Pharm. 2021;13:165-72. doi: 10.22159/ijap.2021v13i2.39895.

Balaji Gupta VLN T, Venkateswara Rao B, Kishore Babu B. RP-HPLC (stability-indicating) based assay method for the simultaneous estimation of doravirine, tenofovir disoproxil fumarate and lamivudine. Int J Appl Pharm. 2021;13:153-9.

International conference on harmonization. ICH harmonized tripartite guideline. Validation of analytical procedures: text and methodology. Vol. Q2(R1); 2005.

Manoranjani M. A study of method development, validation and forced degradation for simultaneous quantification of cisplatin and fluorouracil in bulk and pharmaceutical dosage form by RP-HPLC. J Pharm Sci Res. 2021;13:155-61.

Hemanth Kumar AK, Sudha V, Vijayakumar A, Padmapriyadarsini C. Simultaneous method for the estimation of bidaquiline and delamanid in human plasma using high-performance liquid chromatography. Int J Pharm Pharm Sci. 2021;13:36-40.

Shanmugasundaram P, Kamarapu SK. RP-HPLC method for the simultaneous estimation and validation of amlodipine besylate and atenolol in bulk and tablet dosage form in biorelevant dissolution medium (Fassif). Res J Pharm Technol. 2017;10(10):3379-85. doi: 10.5958/0974-360X.2017.00601.1.

Sruthi A, Uttam Prasad P. Stability indicating method development and validation of fimasartan by reverse-phase high-performance liquid chromatography in bulk and pharmaceutical dosage form. Asian J Pharm Clin Res. 2021;14:138-46.

Lakka Narasimha S, Kuppan Chandrasekar, Srinivas Kona S, Yarra Raviteja. Separation and characterization of new forced degradation products of dasatinib in tablet dosage formulation using LC–MS and stability-indicating HPLC methods. Chromatographia. 2020;83(8):947-62. doi: 10.1007/s10337-020-03920-0.

Chavan Balasaheb B, Vijaya Jyothi P, Kalariya PD, Srinivas R, Talluri MVNK, Pradipbhai D Kalariya. Alcaftadine: selective separation and characterization of degradation products by LC-QTOF-MS/MS. Chromatographia. 2018;81(4):631-8. doi: 10.1007/s10337-018-3489-1.



How to Cite




Original Article(s)